ClinConnect ClinConnect Logo
Search / Trial NCT06378645

Effect of Propofol vs. Sevoflurane on Erections During Narcosis In Transurethral Surgery

Launched by ETIENNE XAVIER KELLER · Apr 18, 2024

Trial Information

Current as of July 05, 2025

Recruiting

Keywords

Transurethral Surgery Penile Tumescence Intraoperative Erection Propofol Sevoflurane Investigator Initiated Trial

ClinConnect Summary

This clinical trial is studying how different types of anesthesia—specifically propofol and sevoflurane—affect the occurrence of unwanted erections during transurethral surgeries, which are procedures done through the urethra. Unwanted erections can complicate surgeries, potentially leading to longer operation times or the need for additional medical interventions. The goal is to find out if using propofol, which is a commonly used medication for sedation, is more or less likely to cause these erections compared to sevoflurane, another anesthetic.

To participate in this study, men aged 18 to 65 who are scheduled for a transurethral operation and have a certain score indicating sexual function (IIEF-5 Score of 12 or higher) may be eligible. Participants should expect to undergo the planned surgery and provide feedback regarding their experience. It's important to note that individuals with certain medical conditions or who are unable to give informed consent cannot join the study. This research is essential as it aims to improve surgical experiences and outcomes for patients undergoing these procedures.

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • Planned transurethral operation in the department of urology.
  • Preoperative IIEF-5 Score ≥12
  • Planned surgery time ≥15min
  • Exclusion Criteria:
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant.
  • Inability to provide informed consent.
  • Contraindications to Propofol or Sevoflurane, e.g. known hypersensitivity or allergy.
  • Known or suspected non-compliance, drug or alcohol abuse.
  • Participation in another study with an investigational drug within the 30 days preceding and during the present study.
  • Previous enrolment into the current study.
  • Enrolment of the investigator, his/her family members, employees and other dependent persons.

About Etienne Xavier Keller

Etienne Xavier Keller is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a strong focus on collaboration and ethical standards, Keller leads multidisciplinary teams in the design and execution of clinical trials across various therapeutic areas. His expertise in regulatory compliance and patient safety ensures that all trials are conducted with the highest level of integrity and scientific rigor. By fostering partnerships with academic institutions and industry stakeholders, Keller aims to accelerate the development of groundbreaking therapies that address unmet medical needs.

Locations

Zürich, , Switzerland

Patients applied

0 patients applied

Trial Officials

Etienne X Keller, Ass Prof, MD

Principal Investigator

University Hospital Zurich, University of Zurich

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported